0000000001227714

AUTHOR

Raffaella Viti

showing 3 related works from this author

Early Treatment in HCV: Is it a Cost-Effective Option from the Italian Perspective?

2016

Background: The aim of this study is to perform an economic analysis to estimate the cost-utility of the early innovative therapy in Italy for managing HCV-infected patients.Methods: The incremental cost-utility analysis was carried out to quantify the benefits of the early treatment approach in HCV subjects. A Markov simulation model including direct and indirect costs and health outcomes was developed from Italian National Healthcare Service and societal perspective. 5,000 Monte Carlo simulations were performed on two distinct scenarios: Standard of Care (SoC) which includes 14.000 Genotype 1 patients in Italy treated with innovative interferon-free in the Fibrosis stage 3 and 4 (F3-F4) v…

education.field_of_studymedicine.medical_specialtyActuarial sciencebusiness.industryPopulationTime horizonIndirect costsSystematic reviewEpidemiologyHealth careMedicineeducationbusinessIncremental cost-effectiveness ratiohealth care economics and organizationsReimbursementSSRN Electronic Journal
researchProduct

Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?

2016

In Italy, the Italian Pharmaceutical Agency (AIFA) criteria used F3–F4 fibrosis stages as the threshold to prioritise the treatment with interferon (IFN)-free regimens, while in genotype 1 chronic hepatitis C (G1 CHC) patients with fibrosis of liver stage 2, an approach with pegylated interferon (PEG-IFN)-based triple therapy with simeprevir was suggested. The key clinical question is whether, in an era of financial constraints, the application of a universal IFN-free strategy in naive G1 CHC patients is feasible within a short time horizon. The aim of this study is to perform an economic analysis to estimate the cost-utility of the early innovative therapy in Italy for managing hepatitis C…

Liver CirrhosisSimeprevirmedicine.medical_specialtyCost-Benefit AnalysisPopulationAntiviral Agents03 medical and health sciencesIndirect costs0302 clinical medicineAntiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome; Pharmacology (medical)SimeprevirRibavirinmedicineHumansPharmacology (medical)030212 general & internal medicineChronicIntensive care medicineeducationReimbursementeducation.field_of_studyCost–benefit analysisbusiness.industryHealth services researchGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CMarkov ChainsQuality-adjusted life yearTreatment OutcomeItalyDisease Progression030211 gastroenterology & hepatologyInterferonsQuality-Adjusted Life YearsbusinessMonte Carlo MethodClinical Drug Investigation
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct